

**Sepsis: Recognition, diagnosis and early management guideline (update)
committee 1 meeting minutes**

Sepsis: recognition, diagnosis and early management – Committee Meeting 1

Date: 09/08/2022

Location: Virtual

Minutes: Final

Committee members present:		
Ann Hoskins (Chair, AH)		Present for notes 1 – 5
Samina Begum		Present for notes 1 – 5
Louise Bradbury		Present for notes 1 – 5
Tumena Corrah		Present for notes 1 – 5
Peter Gosling		Present for notes 1 – 5
Alasdair Gray		Present for notes 1 – 5
Jeremy Henning		Present for notes 1 – 5
Erum Khan		Present for notes 1 – 5
Barry Murphy-Jones		Present for notes 1 – 5
Marlies Ostermann		Present for notes 1 – 5
Giovanni Satta		Present for notes 1 – 5
Sally Wood		Present for notes 1 – 5
Tessa Lewis		Present for notes 1 – 5

In attendance:		
Astrid Aregui (AA)	Medical Editor	Present for notes 1 – 5
Victoria Axe	Guideline Commissioning Manager	Present for notes 1 – 5
Kirsty Hounsell (KH)	Technical Analyst, Health Economics	Present for notes 1 – 5
Jackie Durkin	Administrator	Present for notes 1 – 5
Caroline Mulvihill (CM)	Technical Adviser	Present for notes 1 – 5
Jon Littler (JL)	Project Manager	Present for notes 1 – 5
Lindsay Claxton (LC)	Technical Adviser, Health Economics	Present for notes 1 – 5
Teuta Gjuladin-Hellon (TGH)	Technical Analyst	Present for notes 1 – 5
Apologies:		
Daniel Tuvey	Information Specialist	

1. Welcome and objectives for the meeting

Sepsis: Recognition, diagnosis and early management guideline (update) committee 1 meeting minutes

The Chair (AH) welcomed the committee members and NICE attendees to the first sepsis guideline committee meeting.

AH then informed the committee that apologies had been received which are noted above.

AH then outlined the objectives of the meeting before asking all committee members to verbally declare any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Alasdair Gray	Consultant in Emergency Medicine	Non-financial professional and personal	Co-Chief Investigator. Feasibility of 5% Albumin compared with Balanced crystalloid, intravenous fluid resuscitation in adult Sepsis patients presenting as an emergency to hospital: The ABC Sepsis Trial. Finished recruitment, in follow up. Feasibility trial	Declare and participate Not specific to the scope of the guideline
Alasdair Gray	Consultant in Emergency Medicine	Non-financial professional and personal	Co-investigator. Vasopressors in Sepsis (EVIS). NIHR HTA programme (NIHR132594); (2021-2026). Pragmatic trial of low dose early vasopressor compared with current standard of care in patients with sepsis presenting to UK EDs. Trial currently in set up.	Declare and participate Not specific to the scope of the guideline

AH and senior members of the Developer team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

2. Updating the guideline

AH introduced Astrid Aregui (AA) who took the committee through a brief presentation on how the wording of the original guideline will be brought up to date alongside this update. She then took questions and comments from the committee.

AH thanked AA for her presentation and the work she had prepared and moved on to the next agenda item.

3. Clinical evidence – Stratifying risk of severe illness of death from sepsis

AH introduced Teuta Gjuladin-Hellon (TGH) and Caroline Mulvihill (CM) for the next item for discussion.

TGH began by presenting the clinical evidence for the update before CM joined her in taking the committee through the current recommendations.

4. Drafting recommendations – Stratifying risk of severe illness of death from sepsis

After a short break, TGH and CM then led the committee on a discussion of new recommendations based on the up-to-date evidence.

Sepsis: Recognition, diagnosis and early management guideline (update) committee 1 meeting minutes

AH thanked TGH and CM for their presentations, and the committee for their contributions, and closed this section of the meeting

5. AOB, Summary and next steps

JL advised the committee of the next steps and key dates in development leading up to the consultation on this guideline, including that they would be sent redrafts of the recommendations and evidence review, with changes based on their comments and feedback at the meeting.

AH thanked everyone for their attendance and closed the meeting.

Date of next meeting: 13/09/2022

Location of next meeting: Virtual